 Dihydropyridine derivatives and pharmaceutical composition thereof |
| OF THE INVENTION This invention relates to dihydropyridine derivatives represented by the formula (... |
|
| Use of fedotozine in the treatment of functional states of intestinal obstructions |
| We claim: 1. Process for inhibiting functional ileus in a patient, which consists of administering ... |
|
| Manufacture of pharmaceutical dosage forms |
| OF THE INVENTION The present invention is directed to solid, unit dosage forms primarily for oral ... |
|
| Device comprising liner for protecting fluid sensitive medicament |
| OF THE DRAWING FIGURES Turning now to the drawings in detail, which are examples of various ... |
|
| In situ active compound assembly |
| I claim: 1. A method to modify a target condition contained within an environment with a conjugate ... |
|
| Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein |
| The invention is directed to a method for the prophylaxis or treatment of an animal for systemic ... |
|
| Anti-bronchoconstriction 2-(4'-pyridinyl)-thiazole derivatives, composition, and method of use therefor |
| We claim: 1. A compound having the structural formula I ##STR4## wherein R is cyano, ##STR5## --C(.... |
|
|
Use of specific N-methyl-D-aspartate receptor antagonists in the prevention and treatment of neurodegeneration
| Details |
Inventors: Woodruff, Geoffrey N.; Wong, Erik H. F.; Kemp, John A.;
Assignee: Merck Sharp & Dohme Limited (Hoddesdon, GB2)
Primary Examiner: Robinson; Douglas W.
Assistant Examiner: Kearse; Richard
Attorney, Agent or Firm: Nicholson; William H., DiPrima; Joseph F.
Specific N-methyl-D-aspartate receptor antagonists are useful in the prevention and treatment of neurodegeneration in various pathological states. |
|
DETAILED DESCRIPTION OF THE INVENTION The novel method of treatment of neurodegeneration of this invention comprises the administration to a patient in need of such treatment with an effective amount of an N-methyl-D-aspartate (NMDA) receptor antagonist.
The NMDA receptor antagonists useful in the novel method of treatment of this invention include compounds of the following structural formulae which are described in U.
S.
Pat.
Nos.
4399141; 4374838 and 4064139, the disclosures of which are incorporated herein by reference: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R is (1) hydrogen, (2) C.
sub.
1-5 alkyl, preferably methyl or ethyl, (3) C.
sub.
2-5 alkenyl, preferably vinyl or allyl, (4) phenyl (or substituted phenyl)-(C.
sub.
1-3 alkyl)-, preferably benzyl or substituted benzyl wherein the substituent is halo such as fluoro, chloro or bromo, (5) C.
sub.
3-6 cycloalkyl, preferably cyclopropyl or cyclohexyl, (6) (C.
sub.
3-6 cycloalkyl)-(C.
sub.
1-3 alkyl), or (7) di(C.
sub.
1-5 alkyl)amino-(C.
sub.
1-5 alkyl), especially dimethylaminopropyl; R.
sup.
1 is (1) hydrogen, (2) C.
sub.
1-5 alkyl, preferably methyl or ethyl (3) C.
sub.
2-5 alkenyl, preferably vinyl or allyl (4) phenyl-(C.
sub.
1-3 alkyl), preferably benzyl, (5) C.
sub.
3-6 cycloalkyl, preferably cyclopropyl or cyclohexyl, or (6) (C.
sub.
3-6 cycloalkyl)-(C.
sub.
1-3 alkyl), R.
sup.
2 is (1) C.
sub.
1-5 alkyl, preferably methyl or ethyl (2) C.
sub.
3-5 alkenyl, preferably allyl, (3) phenyl-(C.
sub.
1-3 alkyl), preferably benzyl, (4) (C.
sub.
3-6 cycloalkyl)-(C.
sub.
1-3 alkyl), (5) di(C.
sub.
1-5 alkyl)amino-(C.
sub.
1-5 alkyl), especially dimethylaminopropyl; or (6) C.
sub.
2-3 hydroxyalkyl, preferably hydroxyethyl; and R.
sup.
3 and R.
sup.
4 are independently, (1) hydrogen (2) halogen, such as chloro, bromo, fluoro or iodo, (3) C.
sub.
1-5 alkoxy, preferably methoxy, (4) trifluoromethylthio, (5) cyano, (6) carboxy, or (7) hydroxy.
A preferred group or compounds is that wherein R.
sup.
1 is hydrogen.
Another preferred group of compounds is that wherein R.
sup
|
| Related patents |
|
|
Iron citrate complex, process for its production, and its pharmaceutical
We claim: 1. An iron citrate micellar complex, which is a brown solid having the properties set out below: (a) average composition by weight of about: 10.6% carbon, 2.62%...
|
|
|
Novel 4,5-Bis (4-methoxyphenyl)-2-(pyrrol-2-yl) thiazoles and pharmaceutical composition containing the same
OF INVENTION The 4,5-bis(4-methoxyphenyl)-2-(pyrrol-2-yl)thiazoles of the present invention have the formula (I) as described hereinbefore. In the formula (I), the ...
|
|
|
Specifically .beta.-.beta. cross-linked hemoglobins and method of preparation
The present invention provides a modified hemoglobin comprising hemoglobin which is cross-linked with a cross-linking reagent, said cross-linking reagent being selected ...
|
|
|
Apparatus for manufacturing granulated material
The invention proceeds from the consideration that it is not possible to reduce the width of the slit, especially at high production rates i.e., at high relative ...
|
|
|
Substituted and bridged pyridines useful as calcium channel blockers
OF THE INVENTION The specific substituted and bridged pyridine compounds of this invention are represented by the following general structural formula (I): ##STR1## ...
|
|
|
Ace inhibitors in macular degeneration
OF THE INVENTION The novel method of treatment of senile macular degeneration of this invention comprises the administration to a patient in need of such treatment of ...
|
|
|
Derivatives of 2,3,4,5,6,7-hexahydro-2,7-methano-1,5-benzoxazonines and -1,4-benzoxazonines, processes for their production and their use as pharmaceuticals
We claim: 1. 2,3,4,5,6,7-Hexahydro-2,7-methano-1,5-benzoxazonine and -1,4-benzoxazonine compounds, of the formula ##STR15## wherein: R.sub.1 is hydrogen or C.sub.1 -C....
|
|
|
Novel benzylalcohol derivatives and processes for preparing the same
What we claim is: 1. A compound of the formula: ##STR11## wherein R is a lower alkyl group having 1-4 carbon atoms, or a pharmaceutically acceptable acid addition salt ...
|
|
|
Method of use of bicycloheptane substituted prostaglandin analogs as cardiovascular agents
What is claimed is: 1. A method of inhibiting arachidonic acid-induced platelet aggregation and bronchoconstriction, which comprises administering to the circulatory ...
|
|
|
1-arylsulphonyl-2-piperidinone derivatives, process and intermediates for the preparation thereof, their application as antispasmodics and compositions containing them
What is claimed is: 1. The compound of formula (I): ##STR11## in which R represents the radical ##STR12## in which R.sub.1 at any position on the benzene ring represents ...
|
|
|
Vasodialators 
